Guanfacine extended release - Shire

Drug Profile

Guanfacine extended release - Shire

Alternative Names: Connexyn; GXR; Intuniv; Intunix XR; S-877503; SPD-503

Latest Information Update: 01 Apr 2017

Price : $50

At a glance

  • Originator Shire plc
  • Developer Shionogi; Shire
  • Class Acetamides; Centrally-acting antihypertensives; Chlorobenzenes; Guanidines; Phenylacetates; Small molecules
  • Mechanism of Action Alpha 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder
  • No development reported Anxiety disorders; Generalised anxiety disorder; Social phobia

Most Recent Events

  • 30 Mar 2017 Registered for Attention-deficit hyperactivity disorder (In adolescents, In children) in Japan (PO)
  • 21 Apr 2016 Shionogi and Shire initiate a phase III extension trial for Attention-deficit hyperactivity disorder in Japan (PO) (JapicCTI-163232)
  • 11 Feb 2016 Launched for Attention-deficit hyperactivity disorder (In adolescents, In children) in Denmark, United Kingdom, Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top